Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "1"

Research

Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

disease-deconvolution" identified associations between the parasite-brain interactions and epilepsy, movement disorders, Alzheimer's disease, and cancer.

Research

Role of viral and bacterial pathogens in causing pneumonia among Western Australian children: A case-control study protocol

We aim to determine the contribute of bacteria and virus to childhood CAP to inform further development of effective strategies.

Research

Racial discrimination and child and adolescent health in longitudinal studies: A systematic review

This review emphasises the need to gain evidence for the mechanisms linking early racism exposure to adverse health outcomes in later life

Research

Candidate gene analysis supports a role for polymorphisms at TCF7L2 as risk factors for type 2 diabetes in Sudan

Multiethnic associations between T2D and SNPs at TCF7L2, CAPN10 and HHEX extend to Sub-Saharan Africa, specifically Sudan

Research

Prevalence of Racial Discrimination in a Cohort of Aboriginal and Torres Strait Islander Children

This study looked at the frequency of racism experiences over time in a population of Aboriginal and Torres Strait Islander children

Research

Improving lung health of Aboriginal children hospitalised with chest infections – Aboriginal Children’s Excellent (ACE) Lung Health Study

The ACE project is led by Dr Pamela Laird and aims to improve post-hospitalisation follow-up of Indigenous children hospitalised with acute lower respiratory tract infections.

FAQs

Find answers to frequently asked questions about ORIGINS.

Project websites

These project websites display extended detailed information about specific research areas.

Research

Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma

Medulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely, MYC-amplified Group 3 and TP53-mutated SHH. Using high-throughput assays, six human MB cell lines were screened against a library of 3208 unique compounds. We identified 45 effective compounds from the screen and found that cell cycle checkpoint kinase (CHK1/2) inhibition synergistically enhanced the cytotoxic activity of clinically used chemotherapeutics cyclophosphamide, cisplatin, and gemcitabine.